Ginger and Gut Microbiome (GINGER)
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | 50 - 75 |
Updated: | 3/8/2019 |
Start Date: | November 14, 2018 |
End Date: | May 29, 2020 |
Contact: | Anna Prizment, PhD, MPH |
Email: | prizm001@umn.edu |
Phone: | 612-626-0250 |
Pilot Trial to Examine the Effect of Ginger on the Gut Microbiome (GINGER)
Estimate the impact of a 6‐week daily intake of 2000 mg of ginger extract on the composition
of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e.
examine the change of microbiome over time within and between the subjects..
of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e.
examine the change of microbiome over time within and between the subjects..
This is a pilot trial to evaluate the feasibility of conducting a large randomized trial and
estimate the effects of ginger extract on the gut microbiome. The pilot study will recruit
from multiple sites 95-100 subjects aged 50-75 years old who were diagnosed with colorectal
adenoma within the last five years. There will be 47-50 subjects in the treatment group and
47-50 in the placebo group. The subjects will be randomized to receive either 2000 mg of
ginger extract per day (1000 mg twice a day) or matching placebo.
Subjects will provide three stool specimens for analysis of the intestinal microbiome over a
12-week period at the following intervals: Week 0 (Day 1), Week 6, and Week 12. Although the
gut microbiome is stable within a period of 1-2 months, a control arm will be included to
account for potential dietary and other changes that may affect the gut microbiome. Gut
microbiome composition - the presence, abundance, and diversity of bacterial taxa - will be
derived by sequencing microbial 16S ribosomal RNA genes.
Primary Aims:
Aim 1 is to estimate the impact of a 6-week daily intake of 2000 mg of ginger extract on the
composition of the gut microbiome using a randomized placebo-controlled double-blinded
design, i.e. examine the change of microbiome over time within and between the subjects.
Aim 2 will examine the correlation between the ginger-related changes in microbiome profile
with the levels of circulating biomarkers: urinary Prostaglandin E (PGE) metabolites.
Hypothesis: In the ginger versus placebo arm, gut microbiome will shift towards a lower
proportion of pro-inflammatory, bacteria associated with colorectal cancer (CRC) and higher
proportion of anti-inflammatory, CRC-protective bacteria.
Secondary Aim:
1. At the end of the study, we expect to show that ginger decreases the relative abundance
of pro-inflammatory, CRC-predisposing taxa and increases the abundance of
anti-inflammatory, CRC-protective taxa, i.e., demonstrate that ginger boosts changes in
gut microbiome that are protective against CRC, as well as assess ginger-induced changes
in immune response.
2. The similarities of bacterial profiles will be compared between three time points
baseline and 6 Weeks and 12 Weeks to estimate whether 6-week is a sufficient time for
washout.
estimate the effects of ginger extract on the gut microbiome. The pilot study will recruit
from multiple sites 95-100 subjects aged 50-75 years old who were diagnosed with colorectal
adenoma within the last five years. There will be 47-50 subjects in the treatment group and
47-50 in the placebo group. The subjects will be randomized to receive either 2000 mg of
ginger extract per day (1000 mg twice a day) or matching placebo.
Subjects will provide three stool specimens for analysis of the intestinal microbiome over a
12-week period at the following intervals: Week 0 (Day 1), Week 6, and Week 12. Although the
gut microbiome is stable within a period of 1-2 months, a control arm will be included to
account for potential dietary and other changes that may affect the gut microbiome. Gut
microbiome composition - the presence, abundance, and diversity of bacterial taxa - will be
derived by sequencing microbial 16S ribosomal RNA genes.
Primary Aims:
Aim 1 is to estimate the impact of a 6-week daily intake of 2000 mg of ginger extract on the
composition of the gut microbiome using a randomized placebo-controlled double-blinded
design, i.e. examine the change of microbiome over time within and between the subjects.
Aim 2 will examine the correlation between the ginger-related changes in microbiome profile
with the levels of circulating biomarkers: urinary Prostaglandin E (PGE) metabolites.
Hypothesis: In the ginger versus placebo arm, gut microbiome will shift towards a lower
proportion of pro-inflammatory, bacteria associated with colorectal cancer (CRC) and higher
proportion of anti-inflammatory, CRC-protective bacteria.
Secondary Aim:
1. At the end of the study, we expect to show that ginger decreases the relative abundance
of pro-inflammatory, CRC-predisposing taxa and increases the abundance of
anti-inflammatory, CRC-protective taxa, i.e., demonstrate that ginger boosts changes in
gut microbiome that are protective against CRC, as well as assess ginger-induced changes
in immune response.
2. The similarities of bacterial profiles will be compared between three time points
baseline and 6 Weeks and 12 Weeks to estimate whether 6-week is a sufficient time for
washout.
Inclusion Criteria:
- Colorectal adenoma diagnosis
Exclusion Criteria:
- Allergy or sensitivity to ginger
- Active cancer
- Unstable medical condition
- Unstable diet or weight
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1100 South Washington Avenue
Minneapolis, Minnesota 55415
Minneapolis, Minnesota 55415
Phone: 612-626-0250
Click here to add this to my saved trials
Click here to add this to my saved trials